This company listing is no longer active
SYNLAB Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 2/6
SYNLAB's earnings have been declining at an average annual rate of -9%, while the Healthcare industry saw earnings growing at 3.6% annually. Revenues have been declining at an average rate of 11.5% per year. SYNLAB's return on equity is 3.8%, and it has net margins of 3.4%.
Key information
-9.0%
Earnings growth rate
-14.1%
EPS growth rate
| Healthcare Industry Growth | 15.7% |
| Revenue growth rate | -11.5% |
| Return on equity | 3.8% |
| Net Margin | 3.4% |
| Next Earnings Update | 07 Nov 2024 |
Recent past performance updates
Recent updates
SYNLAB (FRA:SYAB) Might Have The Makings Of A Multi-Bagger
Dec 15
Returns Are Gaining Momentum At SYNLAB (FRA:SYAB)
Sep 10SYNLAB AG (FRA:SYAB) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 14SYNLAB AG (FRA:SYAB) Stock Catapults 27% Though Its Price And Business Still Lag The Market
May 29SYNLAB (FRA:SYAB) Is Investing Its Capital With Increasing Efficiency
May 20Are Investors Undervaluing SYNLAB AG (FRA:SYAB) By 25%?
Sep 26Shareholders Will Be Pleased With The Quality of SYNLAB's (FRA:SYAB) Earnings
Aug 22Revenue & Expenses Breakdown
How SYNLAB makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,615 | 89 | 1,159 | 0 |
| 31 Dec 23 | 2,635 | 92 | 1,163 | 0 |
| 30 Sep 23 | 2,691 | 129 | 1,191 | 0 |
| 30 Jun 23 | 2,772 | 69 | 1,197 | 0 |
| 31 Mar 23 | 2,892 | -37 | 1,213 | 0 |
| 31 Dec 22 | 3,251 | 151 | 1,231 | 0 |
| 30 Sep 22 | 3,542 | 345 | 1,264 | 0 |
| 30 Jun 22 | 3,693 | 404 | 1,265 | 0 |
| 31 Mar 22 | 3,888 | 653 | 1,247 | 0 |
| 31 Dec 21 | 3,765 | 608 | 1,209 | 0 |
| 30 Sep 21 | 3,703 | 591 | 1,155 | 0 |
| 30 Jun 21 | 3,561 | 385 | 1,119 | 0 |
| 31 Mar 21 | 3,080 | 225 | 1,026 | 0 |
| 31 Dec 20 | 2,621 | 36 | 962 | 0 |
| 31 Dec 19 | 1,906 | -122 | 817 | 0 |
| 31 Dec 18 | 1,808 | -51 | 776 | 0 |
| 31 Dec 17 | 1,817 | -166 | 870 | 0 |
| 31 Dec 16 | 1,570 | -230 | 689 | 0 |
| 31 Dec 15 | 845 | -169 | 401 | 0 |
Quality Earnings: SYAB has a large one-off gain of €84.4M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: SYAB became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SYAB has become profitable over the past 5 years, growing earnings by -9% per year.
Accelerating Growth: SYAB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: SYAB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (30.9%).
Return on Equity
High ROE: SYAB's Return on Equity (3.8%) is considered low.